K4 Elite logo K4 Elite
Home / Peptide Library / BPC-157 + TB-500 (Recovery Blend)
Emerging Research

BPC-157 + TB-500 (Recovery Blend)

Tissue Repair & Recovery · ['BPC-157/TB-500', 'Recovery Blend', 'BPC-TB blend']

A research blend pairing BPC-157 with TB-500 (a thymosin beta-4 fragment), two peptides individually studied in preclinical models of wound healing, angiogenesis and musculoskeletal tissue repair. As a two-component mixture it has no single PubChem identifier or molecular formula.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Research Level
Emerging Research
Browse the store →
🧬

This recovery blend combines two peptides commonly paired in the research-chemical literature: BPC-157, a synthetic pentadecapeptide based on a sequence from a gastric protein, and TB-500, a synthetic fragment corresponding to the actin-binding region of thymosin beta-4. Because it is a mixture of two distinct molecules, the blend has no unique chemical formula, molecular weight, or PubChem CID; each component carries its own identifiers.

The blend is categorized under "tissue repair and recovery" because both components have been examined in preclinical models of soft-tissue injury, tendon and muscle healing, angiogenesis, and extracellular-matrix remodeling. The two peptides are often discussed together on the rationale that they engage complementary repair pathways, though the combination itself has not been evaluated in controlled clinical trials.

This entry is provided for laboratory and educational reference only. It summarizes published research on the individual component peptides and is not a description of a product intended for human or veterinary use.

BPC-157 has been associated in animal studies with modulation of the nitric-oxide system, upregulation of growth-factor receptors such as VEGFR2, and promotion of angiogenesis and fibroblast activity in injured tissue, including tendon-to-bone and muscle-injury models. TB-500, as a thymosin beta-4 fragment, is described in the literature as sequestering monomeric G-actin and influencing cell migration, angiogenesis and matrix remodeling.

The pairing is framed as combining BPC-157's angiogenic and growth-factor-associated effects with TB-500's actin-regulatory and cell-migration effects. No study has demonstrated a unique combined mechanism for the two-peptide mixture itself; the rationale is inferred from the separate literature.

  • Tendon and ligament repair — BPC-157 has been studied in rat models of tendon healing and outgrowth (Chang et al., 2011).
  • Muscle injury models — BPC-157 has been examined in rodent muscle-crush and transection experiments (Novinscak et al., 2008; Staresinic et al.).
  • Angiogenesis — BPC-157 has been reviewed for effects on VEGFR2 signaling and vessel formation (Seiwerth et al., 2018).
  • Thymosin beta-4 wound biology — the TB-500 parent molecule has been reviewed for actin regulation, cell migration and repair (Goldstein et al., 2005).
  • Extracellular-matrix remodeling — both peptides have appeared in studies of fibroblast behavior and matrix turnover.
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

No peer-reviewed protocol describes the combined blend. The following are published studies of the individual constituents, reported for reference only. Chang et al. (2011) reported that BPC-157 applied in a rat Achilles-tendon model was associated with increased tendon fibroblast outgrowth and healing markers in vitro and in vivo. Seiwerth et al. (2018) reviewed rodent BPC-157 vascular and wound experiments describing angiogenesis endpoints. Goldstein et al. (2005) summarized thymosin beta-4 animal wound-healing studies, including dermal and corneal repair models.

These summaries describe what investigators did in laboratory animals and are not recommendations. Any doses or routes reported in the cited studies belong to those studies and are not offered here as guidance.

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

BPC-157 (component)Synergistic
Angiogenesis- and growth-factor-associated repair peptide forming one half of the blend.
TB-500 (component)Synergistic
Thymosin beta-4 fragment contributing actin-regulatory and cell-migration mechanisms.
GHK-CuCompatible
Copper tripeptide studied separately for matrix remodeling; combined with these peptides in the GLOW/KLOW blends.
Collagen peptidesNeutral
Dietary collagen is a distinct research topic; no established interaction with these synthetic peptides in the literature.
NSAID research contextCaution
Some BPC-157 animal studies examine gastrointestinal effects in the context of NSAID exposure; relevant when interpreting model design.
  1. Chang et al., BPC 157 and tendon fibroblasts (2011), J Appl Physiol
  2. Seiwerth et al., BPC 157 and blood vessels (2018), Curr Pharm Des
  3. Goldstein et al., Thymosin beta4 in wound repair (2005)
  4. Sikiric et al., Stable gastric pentadecapeptide BPC 157 review (2011), Curr Pharm Des
Is this blend a single compound?
No. It pairs two separate peptides (BPC-157 and TB-500), so it has no single chemical formula, molecular weight, or PubChem identifier.
Why are BPC-157 and TB-500 studied together?
They are often paired on the rationale that they engage complementary repair pathways — angiogenesis and growth-factor signaling for BPC-157, and actin regulation and cell migration for TB-500.
Has the combination been tested in humans?
No controlled human trials of the combined blend appear in the literature. Available evidence is from preclinical animal studies of each peptide separately.
What tissues have the components been studied in?
Preclinical work has examined tendon, ligament, muscle, skin and vascular tissue, among others, largely in rodent models.
Can this be used to treat injuries?
No. This entry is for research and educational reference only. It is not a product description for human or veterinary use and contains no dosing or administration guidance.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.